Citation & Authors
Hepatol Int. 2026;.
ABSTRACT · RESEARCH SUMMARY
Research summary
This Taiwanese National Health Insurance study matched 14,666 pairs of NOAC and warfarin users with HBV, HCV, or alcohol-related liver disease. NOAC use was associated with a lower risk of hepatocellular carcinoma (aHR 0.47; 95% CI 0.26–0.85). The association was more pronounced in HCV and alcohol-related liver disease but was not significant in the HBV subgroup. Missing information on liver disease severity, viral activity, and adherence limits causal interpretation.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
